CCR4 Targeted Antibody Drug Poteligeo Approved by EC for Lymphoma
Kyowa Hakko Kirin, a Japanese pharmaceutical company, recently announced that the European Commission (EC) has approved Poteligeo (mogamulizumab) to treat adult patients with relapsed or refractory mycosis fugoides (MF) or Sezary syndromeRead More…